Press releases

ENYO Pharma strengthens its business team to support International growth

Lyon, the 10th of May 2017. ENYO Pharma, a biopharmaceutical company currently focused on developing treatments for viral infections, has today announced that it is strengthening its business team with the appointment of a CFO and a VP Corporate Development and Strategy, both individuals having strong experience in the pharmaceutical businesses.

Read more »

ENYO Pharma SA announces successful initiation of the Phase 1 clinical programme with EYP001, its lead candidate for the treatment of Chronic Hepatitis B Virus infection.

Lyon, December 16, 2016 – ENYO Pharma SA, a privately held biopharmaceutical company currently focused on developing treatments for viral infections, today announced that the Phase 1 single and multiple ascending dose trial evaluating EYP001 in healthy subjects has been initiated, and that single dose escalation has been completed. The results have shown that EYP001 is safe and well-tolerated at all doses studied in 46 healthy subjects. The safety and pharmacokinetics (PK) analysis of these first Phase 1 data will be complete by Q2 2017.

Read more »

ENYO Pharma receives a €2.5 million grant from EU under the Horizon2020/SME Instrument Phase 2 programme for its project MIMESIS

Lyon, December 5, 2016 – ENYO Pharma, a biopharmaceutical company currently focused on developing treatments for viral infections, today announced that it has received a grant of €2.5 million in response to its application to the highly competitive SME Instrument Phase 2 funding programme (6% success rate).

Read more »

ENYO Pharma strengthens its management team to support its strategy of international growth

Lyon, November 7, 2016 – ENYO Pharma strengthens its management team to support its strategy of international growth.

Read more »

ENYO Pharma announces closing of a €22 million funding round

Lyon, February 3, 2016 – ENYO Pharma announces closing of a €22 million funding round.

Read more »